Acrivon Therapeutics is halting work on developing its lead drug for ovarian and bladder cancers, instead focusing the Eli ...

Analysts at Cantor Fitzgerald pointed out the lead asset, ACR-368, a CHK1/2 inhibitor, as a candidate for Accelerated Approval in endometrial cancer potentially as early as 2026. The optimism is ...

With a $152 million cash position at the end of 2024, Boundless projects operating runway into 2027. “We made important strides in 2024 as we ...

POTENTIATE trial ongoing in patients with oncogene amplified cancers, with initial proof of concept data expected in the second half of 2025 Novel Kinesin program progressing toward development ...

The research team then went on to show that the PARG inhibitor can also be used in combination with other clinically accessible drugs, such as CHK1 and WEE1 inhibitors, to kill ovarian cancer cells ...

and Investigation of Isomerically Hydroxylated Indenoisoquinoline Analogues as Topoisomerase I Poisons Potentiation of the novel topoisomerase I inhibitor indenoisoquinoline LMP-400 by the cell ...

“We made important strides in 2024 as we became a public company and continued to advance BBI-355, our oral, selective CHK1 inhibitor in the Phase 1/2 POTENTIATE trial in patients with oncogene ...